MX2016005969A - (aza)piridopirazolopirimidinonas e indazolopirimidinonas y su uso. - Google Patents

(aza)piridopirazolopirimidinonas e indazolopirimidinonas y su uso.

Info

Publication number
MX2016005969A
MX2016005969A MX2016005969A MX2016005969A MX2016005969A MX 2016005969 A MX2016005969 A MX 2016005969A MX 2016005969 A MX2016005969 A MX 2016005969A MX 2016005969 A MX2016005969 A MX 2016005969A MX 2016005969 A MX2016005969 A MX 2016005969A
Authority
MX
Mexico
Prior art keywords
pyridopyrazolopyrimidinones
indazolopyrimidinones
aza
bleeding
prophylaxis
Prior art date
Application number
MX2016005969A
Other languages
English (en)
Other versions
MX370419B (es
Inventor
Hassfeld Jorma
Stegmann Christian
Köbberling Johannes
Röhrig Susanne
Schlemmer Karl-Heinz
Kinzel Tom
Ellermann Manuel
Beyer Kristin
Sperzel Michael
Cancho Grande Yolanda
Köllnberger Maria
Burkhardt Nils
Schuhmacher Joachim
Werner Matthias
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MX2016005969A publication Critical patent/MX2016005969A/es
Publication of MX370419B publication Critical patent/MX370419B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings

Abstract

La presente solicitud se relaciona con nuevas (aza)piridopirazolopirimidinonas e ndazoIopirimidinonas sustituidas, con procesos para su preparación, en donde los compuestos se usan solos o en combinaciones en un método para el tratamiento y/o profilaxis de enfermedades, en particular para el tratamiento y/o profilaxis de sangrado agudo y recurrente en pacientes con o sin trastornos de sangrado hereditarios o adquiridos subyacentes, en donde el sangrado está asociado con una enfermedad o intervención médica que se elige del grupo que consiste en menorragia, hemorragia posparto, choque hemorrágico, trauma, cirugía, trasplante, infarto, enfermedades hepáticas, angioedema hereditario, sangrado de nariz, y sinovitis y daño de cartílago luego de hemartrosis.
MX2016005969A 2013-11-05 2014-11-03 (aza)piridopirazolopirimidinonas e indazolopirimidinonas y su uso. MX370419B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13191642 2013-11-05
PCT/EP2014/073529 WO2015067549A1 (en) 2013-11-05 2014-11-03 (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones as inhibitors of fibrinolysis

Publications (2)

Publication Number Publication Date
MX2016005969A true MX2016005969A (es) 2016-08-11
MX370419B MX370419B (es) 2019-12-11

Family

ID=49517406

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005969A MX370419B (es) 2013-11-05 2014-11-03 (aza)piridopirazolopirimidinonas e indazolopirimidinonas y su uso.

Country Status (29)

Country Link
US (3) US9598417B2 (es)
EP (1) EP3066100B1 (es)
JP (1) JP6431061B2 (es)
KR (1) KR102312780B1 (es)
CN (1) CN105683194B (es)
AP (1) AP2016009175A0 (es)
AR (1) AR098292A1 (es)
AU (1) AU2014345771B2 (es)
CA (1) CA2929378C (es)
CL (1) CL2016001076A1 (es)
CR (1) CR20160332A (es)
CU (1) CU24361B1 (es)
DO (1) DOP2016000102A (es)
EA (1) EA029373B1 (es)
ES (1) ES2732305T3 (es)
GT (1) GT201600084A (es)
HK (1) HK1223940A1 (es)
IL (1) IL244645B (es)
MA (1) MA39018A1 (es)
MX (1) MX370419B (es)
PE (1) PE20160934A1 (es)
PH (1) PH12016500828A1 (es)
SG (1) SG11201602133RA (es)
TN (1) TN2016000161A1 (es)
TW (1) TWI657089B (es)
UA (1) UA117504C2 (es)
UY (1) UY35809A (es)
WO (1) WO2015067549A1 (es)
ZA (1) ZA201602311B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY35809A (es) 2013-11-05 2015-05-29 Bayer Pharma AG (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos
JP2017533235A (ja) * 2014-11-03 2017-11-09 バイエル ファーマ アクチエンゲゼルシャフト ピペリジニルピラゾロピリミジノン類及びそれらの使用
WO2016173948A1 (en) * 2015-04-30 2016-11-03 Bayer Pharma Aktiengesellschaft Indazolopyrimidinones as fibrinolysis inhibitors
WO2017007917A1 (en) * 2015-07-07 2017-01-12 Mast Therapeutics, Inc. Polyoxyethylene/polyoxypropylene copolymers and fibrinolytic inhibitors, uses thereof and compositions
EP3318563A1 (en) 2016-11-07 2018-05-09 Sanofi Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders
CN110590673A (zh) * 2019-09-02 2019-12-20 南通大学 一种4-氯-7-甲基-1h-吲唑及其化学合成方法
US11654057B2 (en) 2020-04-09 2023-05-23 Bio 54, Llc Devices for bleeding reduction and methods of making and using the same
KR20230142746A (ko) * 2021-02-05 2023-10-11 시노허브 파마슈티컬 씨오., 엘티디 플라스민 억제제, 이의 제조 방법 및 이의 용도
WO2022261154A1 (en) 2021-06-09 2022-12-15 Eli Lilly And Company Substituted fused azines as kras g12d inhibitors
US11642324B1 (en) 2022-03-01 2023-05-09 Bio 54, Llc Topical tranexamic acid compositions and methods of use thereof
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
WO2023194222A1 (en) 2022-04-05 2023-10-12 Socpra Sciences Santé Humaines S.E.C. Inhibitors of chymase for use in the selective resolution of thrombi in thrombotic or thromboembolic disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2192559A5 (en) * 1972-07-17 1974-02-08 Ugine Kuhlmann Pyrimidino (1,2-b) indazole derivs - inters for dyes and pharmaceuticals, from 3-aminoindazoles and beta-ketone derivs
WO2006023000A1 (en) 2004-07-30 2006-03-02 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
AR059224A1 (es) * 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
ES2494390T3 (es) * 2008-06-06 2014-09-15 Sanofi Derivados macrocíclicos de urea y de sulfamida como inhibidores de TAFIa
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
UY32543A (es) 2009-04-07 2010-11-30 Astrazeneca Ab Análogos de isoxazol-3(2h)-ona como agentes terapéuticos
WO2012047156A1 (en) * 2010-10-04 2012-04-12 Astrazeneca Ab Isoxazol-3(2h)-one analogs as plasminogen inhibitors and their use in the treatment of fibrinolysis related diseases
KR20140003438A (ko) * 2010-11-15 2014-01-09 카톨리에케 유니버시테이트 루벤 항바이러스성 축합 헤테로사이클릭 화합물
US8987286B2 (en) * 2010-12-16 2015-03-24 Bayer Intellectual Property Gmbh Substituted pyrimido[1,2-b]indazoles and their use as modulators of the Pi3K/Akt pathway
WO2012082947A1 (en) * 2010-12-16 2012-06-21 Irm Llc Compounds and compositions as tgr5 agonists
UY35809A (es) 2013-11-05 2015-05-29 Bayer Pharma AG (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos
WO2016173948A1 (en) * 2015-04-30 2016-11-03 Bayer Pharma Aktiengesellschaft Indazolopyrimidinones as fibrinolysis inhibitors

Also Published As

Publication number Publication date
CN105683194B (zh) 2018-09-14
US10098883B2 (en) 2018-10-16
KR20160079093A (ko) 2016-07-05
WO2015067549A1 (en) 2015-05-14
ZA201602311B (en) 2017-08-30
JP2016535052A (ja) 2016-11-10
AP2016009175A0 (en) 2016-04-30
NZ718100A (en) 2021-06-25
TWI657089B (zh) 2019-04-21
EA201690935A1 (ru) 2016-10-31
EP3066100A1 (en) 2016-09-14
AR098292A1 (es) 2016-05-26
UA117504C2 (uk) 2018-08-10
IL244645B (en) 2019-06-30
MX370419B (es) 2019-12-11
PE20160934A1 (es) 2016-10-08
CU24361B1 (es) 2018-10-04
CL2016001076A1 (es) 2016-12-09
CA2929378A1 (en) 2015-05-14
MA39018A1 (fr) 2017-06-30
CN105683194A (zh) 2016-06-15
EP3066100B1 (en) 2019-04-17
US10668071B2 (en) 2020-06-02
TW201609728A (zh) 2016-03-16
PH12016500828A1 (en) 2016-06-13
JP6431061B2 (ja) 2018-11-28
DOP2016000102A (es) 2016-06-30
SG11201602133RA (en) 2016-05-30
US20170239251A1 (en) 2017-08-24
GT201600084A (es) 2017-07-12
US20180344739A1 (en) 2018-12-06
IL244645A0 (en) 2016-04-21
HK1223940A1 (zh) 2017-08-11
AU2014345771A1 (en) 2016-04-14
TN2016000161A1 (en) 2017-10-06
ES2732305T3 (es) 2019-11-21
CR20160332A (es) 2016-11-10
CA2929378C (en) 2021-12-07
US20150126449A1 (en) 2015-05-07
AU2014345771B2 (en) 2018-09-13
UY35809A (es) 2015-05-29
KR102312780B1 (ko) 2021-10-15
US9598417B2 (en) 2017-03-21
EA029373B1 (ru) 2018-03-30

Similar Documents

Publication Publication Date Title
PH12016500828A1 (en) (aza) pyridopyrazolopyrimidinones and indazolopyrimidinones as inhibitors of fibrinolysis
CA2897273C (en) Benzylamine derivatives
MX2017005586A (es) Piperidinilpirazolopirimidinonas y utilización de las mismas.
MY185103A (en) Bezylamine derivatives as inhibitors of plasma kallikrein
MX2016001864A (es) Inhibidores de calicreina plasmatica.
PH12016501807A1 (en) Novel compounds
EA201500851A1 (ru) ЭСТРА-1,3,5(10),16-ТЕТРАЕН-3-КАРБОКСАМИДЫ ДЛЯ ИНГИБИРОВАНИЯ 17β-ГИДРОКСИСТЕРОИД-ДЕГИДРОГЕНАЗЫ (AKR1C3)
HRP20210699T1 (hr) Izmijenjeni kolagen
PH12017502112B1 (en) Pyrazole derivatives useful as 5-lipoxygenase activating protein (flap) inhibitors
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
EA201600398A1 (ru) Тиенопиримидины в качестве ингибиторов mknk1 и mknk2
WO2014147182A3 (en) Substituted n-biphenyl-3-acetylamino-benzamides and n-[3-(acetylamino)phenyl]-biphenyl-carboxamides and their use as inhibitors of the wnt signalling pathway
EA201490209A1 (ru) Лечение избыточного менструального кровотечения, обусловленного фибромой матки
PH12016501814A1 (en) Inhibitors of the wnt signalling pathways
PH12015501492A1 (en) Benzylamine derivatives
WO2014108336A8 (en) Pyrazolyl-based carboxamides ii as crac channel inhibitors
WO2014108337A8 (en) Pyrazolyl-based carboxamides i as crac channel inhibitors
MX2016013281A (es) Proteina del factor fviia con vida media extendida para la prevencion y tratamiento de sangrado y regimenes de dosificacion de la misma.
MY187125A (en) Hydrogel formulation for wound healing and/or treatment
MX356388B (es) Inhibidores de la trayectoria de señalizacion de cd95 para el tratamiento de mds.
MA39762A (fr) Nouveaux composés
UA107504C2 (uk) Спосіб лікування п'яткової шпори за індріксоном
RU2011152924A (ru) Способ лечения сдавления головного мозга при тяжелой сочетанной травме

Legal Events

Date Code Title Description
FG Grant or registration